Yervoy OK’d for MSI-H/dMMR mCRC patients

Create PDF

“Metastatic colorectal cancers with dMMR or MSI-H biomarkers can be difficult to treat and some patients may need additional options,” Heinz-Josef Lenz, MD, L. Terrence Lanni chair in gastrointestinal cancer research, University of Southern California Keck School of Medicine, and principal investigator of the study at USC Norris Comprehensive Cancer Center, said in a BMS release. “The FDA’s approval of an I-O/I-O combination provides us with an encouraging approach to address this challenging disease in patients who have progressed following treatment with three standard chemotherapy options.”